This trial will test if a new drug, loncastuximab tesirine, can help control large B-cell lymphoma that has returned or is resistant to CAR T-cell therapy. The safety and possible effects of the new drug will also be studied.
1 Primary · 0 Secondary · Reporting Duration: through study completion and or average of 1 year
30 Total Participants · 1 Treatment Group
Primary Treatment: Loncastuximab Tesirine · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: